Search

Now showing items 1-4 of 4

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

Appel, G. B.; Contreras, G.; Dooley, M. A.; Ginzler, E. M.; Isenberg, D.; Jayne, D.; Li, L-S.; Mysler, E.; Sanchez-Guerrero, J.; Solomons, N.; Wofsy, D.; Abud, C.; Adler, S.; Alarcon, G.; Albuquerque, E.; Almeida, F.; Alvarellos, A.; Appel, G.; Avila, H.; Blume, C.; Boletis, I.; Bonnardeaux, A.; Braun, A.; Buyon, J.; Cervera, R.; Chen, N.; Chen, S.; Da Costa, A. G.; Davids, M. R.; D'Cruz, D.; De Ramon, E.; Deodhar, A.; Doria, A.; Dussol, B.; Emery, P.; Fiechtner, J.; Floege, J.; Fragoso-Loyo, H.; Furie, R.; Ghazalli, R.; Ghossein, C.; Gilkeson, G.; Ginzler, E.; Gordon, C.; Grossman, J.; Gu, J.; Guillevin, L.; Hatron, P. Y.; Herrera, G.; Hiepe, F.; Houssiau, F.; Hubscher, O.; Hura, C.; Kaplan, J.; Kirsztajn, G.; Kiss, E.; Kutty, G. A.; Laville, M.; Lazaro, M.; Lenz, O.; Li, L.; Lightstone, L.; Lim, S.; Malaise, M.; Manzi, S.; Marcos, J.; Meyer, O.; Monge, P.; Naicker, S.; Neal, N.; Neuwelt, M.; Nicholls, K.; Olsen, N.; Ordi-Ros, J.; Ostrov, B.; Pestana, M.; Petri, M.; Pokorny, G.; Pourrat, J.; Qian, J.; Radhakrishnan, J.; Rovin, B.; Roman, J. S.; Shanahan, J.; Shergy, W.; Skopouli, F.; Spindler, A.; Striebich, C.; Sundel, R.; Swanepoel, C.; Si, Y. T.; Tate, G.; Tesar, V.; Tikly, M.; Wang, H.; Yahya, R.; Yu, X.; Zhang, F.; Zoruba, D. (2009)

Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international ...

Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial

Goodwin G.M.; Emsley R.; Rembry S.; Rouillon F. (2009)

Objective: This study evaluates the efficacy of agomelatine, the first antidepressant that is an agonist at MT1/MT2 receptors and an antagonist at 5-HT2C receptor, in the prevention of relapse of depression following ...

A 24-week, multicenter, open-label, randomized study to compare changes in glucose metabolism in patients with schizophrenia receiving treatment with olanzapine, quetiapine, or risperidone

Newcomer J.W.; Ratner R.E.; Eriksson J.W.; Emsley R.; Meulien D.; Miller F.; Leonova-Edlund J.; Leong R.W.; Brecher M. (2009)

Objective: This randomized, 24-week, flexible-dose study compared changes in glucose metabolism in patients with DSM-IV schizophrenia receiving initial exposure to olanzapine, quetiapine, or risperidone. Method: The ...

Changes in erythrocyte membrane fatty acids during a clinical trial of eicosapentaenoic acid (EPA) supplementation in schizophrenia

Van Rensburg, S. J.; Smuts, C. M.; Hon, D.; Kidd, M.; Van Der Merwe, S.; Myburgh, C.; Oosthuizen, P.; Emsley, R. (2009)

In a previously reported double-blind, placebo-controlled trial of eicosapentaenoic acid (EPA) as supplemental treatment in 40 patients with schizophrenia, we found significant improvement in symptoms as measured by the ...